PLoS ONE:日本开发胰腺癌细胞吸收化疗药物的新疗法

2012-07-19 蓝建中 新华网

  日前,日本札幌医科大学教授加藤淳二率领的研究小组在新一期美国《公共科学图书馆—综合》(PLoS ONE)上报告说,他们开发出一种治疗胰腺癌的新疗法,即利用癌细胞能吸收海藻糖的性质,在化疗过程中使癌细胞直接“吃药”,从而能够减少药量,并减小化疗药物对健康细胞的影响。 研究小组发现,胰腺癌细胞具有活跃吸收海藻糖的性质,于是将海藻糖与内部包有化疗药物的称为脂质体的薄膜结合在一起,然后注

 

日前,日本札幌医科大学教授加藤淳二率领的研究小组在新一期美国《公共科学图书馆—综合》(PLoS ONE)上报告说,他们开发出一种治疗胰腺癌的新疗法,即利用癌细胞能吸收海藻糖的性质,在化疗过程中使癌细胞直接“吃药”,从而能够减少药量,并减小化疗药物对健康细胞的影响。

研究小组发现,胰腺癌细胞具有活跃吸收海藻糖的性质,于是将海藻糖与内部包有化疗药物的称为脂质体的薄膜结合在一起,然后注射到小鼠体内,结果成功地将药物输送到了癌细胞处。

研究小组成员、札幌医科大学讲师泷本理修说:“这是一种让癌细胞自己积极吸收化疗药物的新疗法。”研究小组今后准备开展临床试验。

研究小组认为,基于癌细胞吸收海藻糖的性质,这种方法还能够用于治疗胃癌、大肠癌和胆管癌。

doi:10.1371/journal.pone.0039545
PMC:

PMID:

Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach

Makoto Yoshida1,2, Rishu Takimoto1,2, Kazuyuki Murase1, Yasushi Sato1, Masahiro Hirakawa1,2, Fumito Tamura1,2, Tsutomu Sato1,3, Satoshi Iyama1, Takahiro Osuga1, Koji Miyanishi1, Kohichi Takada1, Tsuyoshi Hayashi1, Masayoshi Kobune3, Junji Kato

Owing to its aggressiveness and the lack of effective therapies, pancreatic ductal adenocarcinoma has a dismal prognosis. New strategies to improve treatment and survival are therefore urgently required. Numerous fucosylated antigens in sera serve as tumor markers for cancer detection and evaluation of treatment efficacy. Increased expression of fucosyltransferases has also been reported for pancreatic cancer. These enzymes accelerate malignant transformation through fucosylation of sialylated precursors, suggesting a crucial requirement for fucose by pancreatic cancer cells. With this in mind, we developed fucose-bound nanoparticles as vehicles for delivery of anticancer drugs specifically to cancer cells. L-fucose-bound liposomes containing Cy5.5 or Cisplatin were effectively delivered into CA19-9 expressing pancreatic cancer cells. Excess L-fucose decreased the efficiency of Cy5.5 introduction by L-fucose-bound liposomes, suggesting L-fucose-receptor-mediated delivery. Intravenously injected L-fucose-bound liposomes carrying Cisplatin were successfully delivered to pancreatic cancer cells, mediating efficient tumor growth inhibition as well as prolonging survival in mouse xenograft models. This modality represents a new strategy for pancreatic cancer cell-targeting therapy.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
    2012-07-21 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
    2012-07-21 kcb074
  7. [GetPortalCommentsPageByObjectIdResponse(id=1804981, encodeId=843118049818c, content=<a href='/topic/show?id=6c93e7831af' target=_blank style='color:#2F92EE;'>#细胞吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77831, encryptionId=6c93e7831af, topicName=细胞吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Feb 12 01:10:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789457, encodeId=7b951e8945718, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Mar 07 10:10:00 CST 2013, time=2013-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251901, encodeId=d8ff125190112, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294116, encodeId=6a0c129411678, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506691, encodeId=cba3150669183, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554408, encodeId=47f2155440877, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581726, encodeId=e1b91581e26b8, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jul 21 02:10:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]

相关资讯

新版日本《胃癌处理规约》解读

  日本从1962年开始制定和出版了第1版《胃癌临床和病理处理规约》,经过多次修订,到目前已出版了第14版《胃癌处理规约》。可以说,《胃癌处理规约》[以下简称《规约》]反映了日本胃癌诊疗发展的历史,是日本各个时期胃癌诊治的“金标准”。第13版和第14版《胃癌处理规约》的出版时间间隔10年,在这10年间,胃癌的病理学和临床研究均有了显著的进步。2001年3月,日本制定了《胃癌治疗指南》 [以下简称《